Symbols / NAUT Stock $2.59 +0.78% Nautilus Biotechnology, Inc.

Healthcare • Biotechnology • United States • NCM
NAUT (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Mr. Sujal M. Patel
Exch · Country NCM · United States
Market Cap 327.80M
Enterprise Value 251.88M
Income -59.00M
Sales —
FCF (ttm) -28.78M
Book/sh 1.24
Cash/sh 0.82
Employees 130
Insider 10d —
IPO Aug 07, 2020
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -3.50
PEG —
P/S —
P/B 2.09
P/C —
EV/EBITDA -3.87
EV/Sales —
Quick Ratio 13.00
Current Ratio 13.32
Debt/Eq 19.12
LT Debt/Eq —
EPS (ttm) -0.47
EPS next Y -0.74
EPS Growth —
Revenue Growth —
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-04-28
Earnings (prior) 2026-02-26
ROA -19.26%
ROE -32.27%
ROIC —
Gross Margin 0.00%
Oper. Margin 0.00%
Profit Margin 0.00%
Shs Outstand 126.56M
Shs Float 46.03M
Insider Own 33.48%
Instit Own 44.99%
Short Float 1.29%
Short Ratio 1.51
Short Interest 638.94K
52W High 4.31
vs 52W High -39.91%
52W Low 0.62
vs 52W Low 317.74%
Beta 0.99
Impl. Vol. 87.50%
Rel Volume 1.16
Avg Volume 297.68K
Volume 346.25K
Target (mean) $4.00
Tgt Median $4.00
Tgt Low $4.00
Tgt High $4.00
# Analysts 1
Recom None
Prev Close $2.57
Price $2.59
Change 0.78%
About

Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome in the United States. The company develops Nautilus Voyager Platform, which includes an end-to-end solution comprising instruments, reagents, consumables, and software analysis. It also provides nautilus voyager instrument, a high-resolution optical imaging system with integrated fluidics and liquid handling sub-system to deposit protein libraries onto a flow cell and to process labeled multi-affinity reagent binding and imaging cycles rapidly to decode and quantify the proteins present in biological samples. In addition, the company offers single-molecule library preparation kits, flow cells, affinity reagents, and instrument run buffers to perform multi-cycle analysis runs. It has a research collaboration agreement Genentech, Buck Institute, Allen Institute, Cornell University and the Qatar Foundation, and Michael J. Fox Foundation. Nautilus Biotechnology, Inc. was founded in 2016 and is headquartered in Seattle, Washington.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$4.00
Mean price target
2. Current target
$2.59
Latest analyst target
3. DCF / Fair value
$-4.09
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$2.59
Low
$4.00
High
$4.00
Mean
$4.00

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-02-27 main Guggenheim Buy → Buy $4
2024-12-05 down Goldman Sachs Neutral → Sell $2
2024-06-27 init Guggenheim — → Buy $6
2023-08-03 reit Morgan Stanley Equal-Weight → Equal-Weight $6
2022-08-03 main Morgan Stanley — → Equal-Weight $6
2022-08-03 main Goldman Sachs — → Neutral $2
2022-07-14 main Goldman Sachs — → Neutral $4
2022-04-13 main Goldman Sachs — → Neutral $5
2022-01-06 init Morgan Stanley — → Equal-Weight $8
2021-11-02 init Cowen & Co. — → Outperform —
2021-08-04 init Goldman Sachs — → Neutral $10
2021-07-13 init Jefferies — → Buy $13
News
RSS: Latest NAUT news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-03-04 PATEL SUJAL M Chief Executive Officer — 25,000 $2.61 $65,238
2025-11-06 SUZUKI KENTARO Officer — 4,000 $1.49 $5,960
2025-09-08 PATEL SUJAL M Chief Executive Officer — 200,000 $0.67 $135,575
2025-09-04 MURPHY MATTHEW B J.D. General Counsel — 20,000 $0.64 $12,858
2025-05-29 MOWRY ANNA Chief Financial Officer — 15,000 $0.77 $11,488
2025-05-12 MALLICK PARAG Officer, Director and Beneficial Owner — 13,500 $0.73 $9,885
2025-03-20 PATEL SUJAL M Chief Executive Officer — 77,233 $0.99 $76,918
2024-09-23 GODWIN MARY ELIZABETH Officer — 47,031 $2.86 $134,744
2024-09-23 GODWIN MARY ELIZABETH Officer — 47,031 $0.46 $21,634
2024-09-17 GODWIN MARY ELIZABETH Officer — 35,000 $2.85 $99,869
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
0.00
0.00
0.00
0.00
Operating Revenue
0.00
0.00
0.00
0.00
Operating Expense
66.84
-17.97%
81.48
+6.99%
76.15
+19.70%
63.62
Research And Development
41.11
-18.56%
50.48
+6.83%
47.25
+25.43%
37.67
Selling General And Administration
25.73
-17.01%
31.00
+7.26%
28.90
+11.39%
25.95
General And Administrative Expense
25.73
-17.01%
31.00
+7.26%
28.90
+11.39%
25.95
Other Gand A
25.73
-17.01%
31.00
+7.26%
28.90
+11.39%
25.95
Total Expenses
66.84
-17.97%
81.48
+6.99%
76.15
+19.70%
63.62
Operating Income
-66.84
+17.97%
-81.48
-6.99%
-76.15
-19.70%
-63.62
EBITDA
-60.37
+19.55%
-75.04
-6.52%
-70.45
-17.02%
-60.20
Normalized EBITDA
-60.37
+19.55%
-75.04
-6.52%
-70.45
-17.02%
-60.20
Reconciled Depreciation
6.46
+0.43%
6.44
+12.83%
5.71
+67.01%
3.42
EBIT
-66.84
+17.97%
-81.48
-6.99%
-76.15
-19.70%
-63.62
Net Income
-59.00
+16.64%
-70.78
-11.16%
-63.67
-9.93%
-57.92
Pretax Income
-59.00
+16.64%
-70.78
-11.16%
-63.67
-9.93%
-57.92
Net Non Operating Interest Income Expense
7.87
-27.01%
10.78
-14.10%
12.55
+115.78%
5.82
Net Interest Income
7.87
-27.01%
10.78
-14.10%
12.55
+115.78%
5.82
Interest Income Non Operating
7.87
-27.01%
10.78
-14.10%
12.55
+115.78%
5.82
Interest Income
7.87
-27.01%
10.78
-14.10%
12.55
+115.78%
5.82
Other Income Expense
-0.03
+61.90%
-0.08
-15.07%
-0.07
+40.16%
-0.12
Other Non Operating Income Expenses
-0.03
+61.90%
-0.08
-15.07%
-0.07
+40.16%
-0.12
Tax Rate For Calcs
0.00
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-59.00
+16.64%
-70.78
-11.16%
-63.67
-9.93%
-57.92
Net Income From Continuing Operation Net Minority Interest
-59.00
+16.64%
-70.78
-11.16%
-63.67
-9.93%
-57.92
Net Income From Continuing And Discontinued Operation
-59.00
+16.64%
-70.78
-11.16%
-63.67
-9.93%
-57.92
Net Income Continuous Operations
-59.00
+16.64%
-70.78
-11.16%
-63.67
-9.93%
-57.92
Normalized Income
-59.00
+16.64%
-70.78
-11.16%
-63.67
-9.93%
-57.92
Net Income Common Stockholders
-59.00
+16.64%
-70.78
-11.16%
-63.67
-9.93%
-57.92
Diluted EPS
—
-0.56
-9.80%
-0.51
-10.87%
-0.46
Basic EPS
—
-0.56
-9.80%
-0.51
-10.87%
-0.46
Basic Average Shares
—
125.43
+0.41%
124.92
+0.26%
124.59
Diluted Average Shares
—
125.43
+0.41%
124.92
+0.26%
124.59
Diluted NI Availto Com Stockholders
-59.00
+16.64%
-70.78
-11.16%
-63.67
-9.93%
-57.92
Line Item Trend 2023-12-31
Total Assets
305.56
Current Assets
176.84
Cash Cash Equivalents And Short Term Investments
173.42
Cash And Cash Equivalents
19.40
Other Short Term Investments
154.02
Prepaid Assets
—
Other Current Assets
3.42
Total Non Current Assets
128.73
Net PPE
36.90
Gross PPE
41.53
Accumulated Depreciation
-4.63
Properties
0.00
Buildings And Improvements
32.63
Machinery Furniture Equipment
0.55
Construction In Progress
0.90
Other Properties
7.33
Leases
0.12
Investments And Advances
90.65
Non Current Deferred Assets
—
Non Current Prepaid Assets
—
Other Non Current Assets
1.18
Total Liabilities Net Minority Interest
40.21
Current Liabilities
9.12
Payables And Accrued Expenses
2.62
Payables
1.64
Accounts Payable
1.64
Current Accrued Expenses
0.98
Pensionand Other Post Retirement Benefit Plans Current
2.59
Current Debt And Capital Lease Obligation
3.54
Current Capital Lease Obligation
3.54
Other Current Liabilities
0.38
Total Non Current Liabilities Net Minority Interest
31.09
Long Term Debt And Capital Lease Obligation
31.09
Long Term Capital Lease Obligation
31.09
Preferred Securities Outside Stock Equity
—
Stockholders Equity
265.35
Common Stock Equity
265.35
Capital Stock
0.01
Common Stock
0.01
Preferred Stock
0.00
Share Issued
125.07
Ordinary Shares Number
125.07
Treasury Shares Number
0.00
Additional Paid In Capital
467.83
Retained Earnings
-202.24
Gains Losses Not Affecting Retained Earnings
-0.26
Other Equity Adjustments
-0.26
Total Equity Gross Minority Interest
265.35
Total Capitalization
265.35
Working Capital
167.72
Invested Capital
265.35
Total Debt
34.63
Capital Lease Obligations
34.63
Net Tangible Assets
265.35
Tangible Book Value
265.35
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-50.70
+14.29%
-59.15
-14.38%
-51.71
-12.89%
-45.81
Cash Flow From Continuing Operating Activities
-50.70
+14.29%
-59.15
-14.38%
-51.71
-12.89%
-45.81
Net Income From Continuing Operations
-59.00
+16.64%
-70.78
-11.16%
-63.67
-9.93%
-57.92
Depreciation Amortization Depletion
6.46
+0.43%
6.44
+12.83%
5.71
+67.01%
3.42
Depreciation
6.46
+0.43%
6.44
+12.83%
5.71
+67.01%
3.42
Depreciation And Amortization
6.46
+0.43%
6.44
+12.83%
5.71
+67.01%
3.42
Other Non Cash Items
—
0.76
—
—
Stock Based Compensation
6.84
-46.11%
12.70
+4.65%
12.14
+16.93%
10.38
Operating Gains Losses
—
0.08
—
—
Gain Loss On Sale Of PPE
—
0.08
0.00
0.00
Change In Working Capital
-3.58
+34.35%
-5.46
-69.59%
-3.22
-308.50%
-0.79
Change In Prepaid Assets
0.54
-18.32%
0.67
+181.12%
-0.82
-208.60%
0.76
Change In Payables And Accrued Expense
0.56
+128.35%
-1.98
-343.83%
0.81
+632.89%
-0.15
Change In Accrued Expense
0.63
+145.03%
-1.40
-435.01%
0.42
+1.96%
0.41
Change In Payable
-0.07
+88.06%
-0.58
-247.07%
0.39
+170.05%
-0.56
Change In Account Payable
-0.07
+88.06%
-0.58
-247.07%
0.39
+170.05%
-0.56
Change In Other Current Liabilities
-4.69
-12.96%
-4.15
-29.36%
-3.21
-130.46%
-1.39
Investing Cash Flow
35.22
-46.83%
66.25
+251.48%
-43.73
-69.91%
-25.74
Cash Flow From Continuing Investing Activities
35.22
-46.83%
66.25
+251.48%
-43.73
-69.91%
-25.74
Net PPE Purchase And Sale
-1.28
+39.82%
-2.12
+13.10%
-2.44
-5.08%
-2.32
Purchase Of PPE
-1.28
+39.82%
-2.12
+13.10%
-2.44
-5.08%
-2.32
Capital Expenditure
-1.28
+39.82%
-2.12
+13.10%
-2.44
-5.08%
-2.32
Net Investment Purchase And Sale
36.50
-47.20%
69.13
+267.42%
-41.29
-76.35%
-23.42
Purchase Of Investment
-72.49
+15.98%
-86.28
+23.57%
-112.89
+39.50%
-186.59
Sale Of Investment
108.99
-29.87%
155.41
+117.06%
71.60
-56.12%
163.18
Net Other Investing Changes
—
-0.76
—
—
Financing Cash Flow
0.21
-81.29%
1.14
+210.87%
0.37
-34.52%
0.56
Cash Flow From Continuing Financing Activities
0.21
-81.29%
1.14
+210.87%
0.37
-34.52%
0.56
Proceeds From Stock Option Exercised
0.21
-81.29%
1.14
+210.87%
0.37
-34.52%
0.56
Net Other Financing Charges
—
—
—
—
Changes In Cash
-15.26
-284.97%
8.25
+108.68%
-95.08
-33.94%
-70.98
Beginning Cash Position
28.65
+40.44%
20.40
-82.34%
115.48
-38.07%
186.46
End Cash Position
13.39
-53.26%
28.65
+40.44%
20.40
-82.34%
115.48
Free Cash Flow
-51.97
+15.17%
-61.27
-13.14%
-54.15
-12.51%
-48.13
Amortization Of Securities
-1.42
+49.36%
-2.80
-5.45%
-2.66
-198.76%
-0.89
Issuance Of Capital Stock
—
—
—
—
Net Preferred Stock Issuance
—
—
—
—
Preferred Stock Issuance
—
—
—
—
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category